South Dakota Investment Council Reduces Holdings in DexCom, Inc. (NASDAQ:DXCM)

South Dakota Investment Council trimmed its stake in DexCom, Inc. (NASDAQ:DXCM) by 5.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 20,780 shares of the medical device company’s stock after selling 1,100 shares during the period. South Dakota Investment Council’s holdings in DexCom were worth $2,579,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of DXCM. Valley National Advisers Inc. grew its position in shares of DexCom by 73.0% in the 4th quarter. Valley National Advisers Inc. now owns 244 shares of the medical device company’s stock valued at $30,000 after buying an additional 103 shares during the last quarter. MV Capital Management Inc. grew its position in shares of DexCom by 99.3% in the 4th quarter. MV Capital Management Inc. now owns 277 shares of the medical device company’s stock valued at $34,000 after buying an additional 138 shares during the last quarter. Washington Trust Advisors Inc. boosted its stake in DexCom by 120.6% during the 4th quarter. Washington Trust Advisors Inc. now owns 353 shares of the medical device company’s stock worth $44,000 after purchasing an additional 193 shares during the period. NBC Securities Inc. acquired a new stake in DexCom during the 3rd quarter worth $47,000. Finally, Thompson Siegel & Walmsley LLC acquired a new stake in DexCom during the 3rd quarter worth $48,000. 97.75% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at DexCom

In other news, CFO Jereme M. Sylvain sold 3,363 shares of DexCom stock in a transaction dated Tuesday, February 20th. The stock was sold at an average price of $116.73, for a total transaction of $392,562.99. Following the sale, the chief financial officer now directly owns 71,142 shares of the company’s stock, valued at $8,304,405.66. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other DexCom news, EVP Sadie Stern sold 20,321 shares of the company’s stock in a transaction that occurred on Tuesday, March 12th. The stock was sold at an average price of $133.61, for a total value of $2,715,088.81. Following the transaction, the executive vice president now directly owns 80,441 shares of the company’s stock, valued at approximately $10,747,722.01. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Jereme M. Sylvain sold 3,363 shares of the company’s stock in a transaction that occurred on Tuesday, February 20th. The shares were sold at an average price of $116.73, for a total value of $392,562.99. Following the completion of the transaction, the chief financial officer now directly owns 71,142 shares in the company, valued at $8,304,405.66. The disclosure for this sale can be found here. Insiders have sold a total of 189,375 shares of company stock valued at $25,530,859 over the last ninety days. Corporate insiders own 0.41% of the company’s stock.

Analysts Set New Price Targets

A number of analysts recently weighed in on DXCM shares. UBS Group increased their price target on shares of DexCom from $153.00 to $163.00 and gave the stock a “buy” rating in a research note on Wednesday, April 10th. Citigroup increased their price target on shares of DexCom from $148.00 to $161.00 and gave the stock a “buy” rating in a research note on Wednesday, April 3rd. Royal Bank of Canada assumed coverage on shares of DexCom in a research note on Tuesday, March 12th. They issued an “outperform” rating and a $165.00 target price for the company. StockNews.com cut shares of DexCom from a “buy” rating to a “hold” rating in a research note on Tuesday. Finally, Raymond James increased their price target on shares of DexCom from $147.00 to $151.00 and gave the company a “strong-buy” rating in a report on Tuesday, January 23rd. Three analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $141.40.

DexCom Stock Performance

Shares of NASDAQ DXCM opened at $137.87 on Thursday. The company has a 50-day simple moving average of $130.58 and a 200-day simple moving average of $117.88. The company has a debt-to-equity ratio of 1.18, a current ratio of 2.84 and a quick ratio of 2.48. DexCom, Inc. has a 12 month low of $74.75 and a 12 month high of $142.00. The company has a market cap of $54.60 billion, a PE ratio of 105.25, a price-to-earnings-growth ratio of 2.30 and a beta of 1.20.

DexCom (NASDAQ:DXCM) last released its earnings results on Thursday, February 8th. The medical device company reported $0.50 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.43 by $0.07. DexCom had a net margin of 14.95% and a return on equity of 28.31%. The business had revenue of $1.03 billion for the quarter, compared to analysts’ expectations of $1.02 billion. During the same period last year, the company earned $0.34 earnings per share. The company’s quarterly revenue was up 26.9% on a year-over-year basis. On average, equities analysts anticipate that DexCom, Inc. will post 1.76 earnings per share for the current year.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.